ABOUT

A clinical pharmacokinetics network for the Midlands

For over 10 years our group of like minded scientists based within Aston University in central Birmingham, have focused on the provision of pharmacokinetics research, both pre-clinical and clinical on a national and international level. Our research focuses on developing virtual patients, with which to study the pharmacokinetics of drugs during drug discovery and development.

We also work across clinical areas, applying population pharmacokinetics to the study and causes of variability in drug concentrations among individuals, through sparse (plasma) sampling and mathematical models to explain sources of variability and approaches to dose optimisation.

We are keen to work with colleagues within the Midlands, please get in touch to discuss opportunities for collaboration.

WELCOME TO THE

WEST MIDLANDS PHARMACOKINETICS NETWORK

PHARMACOKINETICS WORKSHOP

We provide basic and advanced training in pharmacokinetics to individuals with an academic or clinical background. We can also delivery bespoke training in a range of pharmacokinetics topics. For a current list of free and paid training workshops, please click below.

Go To Workshop Page

PK/PD ANALYSIS

We can conduct PK/PD in-vitro and in-vivo (rodent) studies to support data generation and analysis. We are supported by the necessary expertise and apparatus for biophase analysis (HPLC, Mass-Spec etc)

Get in Touch

MODELLING

Our in-silico modeling suite is equipped with a range of computational pharmacokinetic modeling software to support both non-compartmental and compartmental modeling in addition to a suite of packages to develop a-priori mechanistic models and population pharmacokinetic models.

Get in Touch

REPRESENTATIVE PUBLISHED WORK

QUETIAPINE DOSE OPTIMISATION DURING GESTATION: A PHARMACOKINETICS MODELLING STUDY

February 3rd 2020

Badhan RKS, Macfarlane H. Quetiapine dose optimisation during gestation: a
pharmacokinetic modelling study. J Pharm Pharmacol. 2020 Feb 3. doi:
10.1111/jphp.13236. [Epub ahead of print] PubMed PMID: 32012278.

THE OPTIMISATION OF METHADONE DOSING WHILST TREATING WITH RIFAMPICIN: A PHARMACOKINETIC MODELLING STUDY

JULY 1ST 2019

Badhan RKS, Gittins R, Al Zabit D. The optimization of methadone dosing whilst
treating with rifampicin: A pharmacokinetic modeling study. Drug Alcohol Depend.
2019 Jul 1;200:168-180. doi: 10.1016/j.drugalcdep.2019.03.013. Epub 2019 May 20.
PubMed PMID: 31122724.

THE IMPACT OF CYP2B6 POLYMORPHISMS ON THE INTERACTIONS OF EFAVIRENZ WITH LUMEFANTRINE: IMPLICATIONS FOR PAEDIATRIC ANTIMALARIAL THERAPY

July 2018

Zakaria Z, Badhan RKS. The impact of CYP2B6 polymorphisms on the interactions
of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy.
Eur J Pharm Sci. 2018 Jul 1;119:90-101. doi: 10.1016/j.ejps.2018.04.012. Epub
2018 Apr 7. PubMed PMID: 29635009.

FIXED-DOSE COMBINATION ORALLY DISINTEGRATING TABLETS TO TREAT CARDIOVASCULAR DISEASE: FORMULATION, IN VITRO CHARACTERIZATION AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO ASSESS BIOAVAILABILITY.

March 2017

Dennison TJ, Smith JC, Badhan RK, Mohammed AR. Fixed-dose combination orally
disintegrating tablets to treat cardiovascular disease: formulation, in vitro
characterization and physiologically based pharmacokinetic modeling to assess
bioavailability. Drug Des Devel Ther. 2017 Mar 16;11:811-826. doi:
10.2147/DDDT.S126035. eCollection 2017. PubMed PMID: 28352156; PubMed Central
PMCID: PMC5358997.